B-cell type acute leukaemia is a fast-growing blood cancer that can affect people at any age, though it is most common in young children. While the diagnosis can be overwhelming, understanding the treatment options available—from established therapies to innovative approaches being tested in clinical trials—can help patients and families navigate this challenging journey with greater confidence.

How Treatment Works Against This Blood Cancer

Treatment for B-cell acute lymphoblastic leukaemia focuses on bringing the disease into complete remission, preventing its return, and helping patients maintain the best possible quality of life. The main goal is to eliminate the abnormal white blood cells called lymphoblasts that crowd out healthy blood cells in the bone marrow, the soft inner part of bones where blood cells are made. When lymphoblasts take over the bone marrow, the body cannot produce enough normal red blood cells, white blood cells, and platelets, which leads to symptoms like fatigue, frequent infections, and easy bleeding or bruising.^[2]

Treatment strategies depend heavily on several factors including the patient’s age, the specific genetic features of the leukaemia cells, and how well the disease responds to initial therapy. Children with B-cell acute lymphoblastic leukaemia often have very high cure rates, with around 85% of children staying cancer-free after five years of completing treatment. The five-year survival rate reaches above 90% in children, while adults face more challenges, with survival rates around 40% for those over age 20.^[2]

Medical societies have developed standard treatment protocols that are approved and widely used across healthcare systems. These protocols represent the best current knowledge about how to treat the disease effectively. At the same time, researchers continue to explore new therapies through clinical trials, testing innovative drugs and treatment combinations that may offer better outcomes, fewer side effects, or both. Some patients may benefit from participating in these studies, which provide access to cutting-edge treatments while contributing to medical knowledge that will help future patients.^[11]

Standard Treatment Approaches

The conventional treatment of B-cell acute lymphoblastic leukaemia follows a structured pathway that unfolds in several distinct phases. Each phase has specific goals and uses different combinations of medications to attack the cancer from multiple angles. This approach has been refined over decades and represents the foundation of care for most patients.

Treatment typically begins with an induction phase, which aims to achieve complete remission by eliminating leukaemia cells from the blood and bone marrow. During this phase, which usually lasts about a month, patients receive intensive chemotherapy—powerful drugs that kill rapidly dividing cancer cells. Multiple chemotherapy drugs are used together because cancer cells can develop resistance to single agents. The specific drugs chosen depend on whether the leukaemia cells have certain genetic features, particularly the presence of something called the Philadelphia chromosome.^[15]

For patients whose leukaemia cells do not have the Philadelphia chromosome (called Philadelphia-negative or Ph-negative disease), doctors often use what are known as “pediatric-inspired” protocols. These intensive chemotherapy regimens were originally developed for children and have been adapted for adults because they produce better results than older adult treatment protocols. The drugs used during induction commonly include medications such as vincristine (which disrupts cancer cell division), daunorubicin or doxorubicin (which damage cancer cell DNA), L-asparaginase (which deprives cancer cells of nutrients they need to grow), and corticosteroids like prednisone or dexamethasone (which can directly kill lymphoblasts).^[17]

If the leukaemia cells do carry the Philadelphia chromosome (Ph-positive disease), treatment includes tyrosine kinase inhibitors or TKIs. These targeted drugs, such as imatinib, dasatinib, or ponatinib, specifically block the abnormal protein produced by the Philadelphia chromosome that drives cancer cell growth. The use of TKIs has dramatically improved outcomes for Ph-positive patients and allows doctors to reduce the intensity of chemotherapy in many cases. TKIs are taken by mouth, usually daily, and work by interfering with specific molecular signals inside leukaemia cells.^[3][17]

Once remission is achieved, treatment moves into a consolidation phase, also called intensification. This phase aims to eliminate any remaining leukaemia cells that might be hiding in the body but are too few to detect with standard tests. Consolidation typically lasts several months and uses high doses of chemotherapy drugs, sometimes including different agents than those used during induction. The goal is to prevent the cancer from returning, a situation called relapse.^[10]

Following consolidation, patients enter a maintenance phase, which is much less intensive but continues for a longer period—typically two to three years in total. During maintenance, patients take lower doses of chemotherapy drugs, often including daily oral medications and monthly treatments given in a clinic or hospital. The purpose of maintenance therapy is to keep any residual cancer cells from growing back. Some patients may also receive treatment directed at the central nervous system (brain and spinal cord) to prevent leukaemia from spreading to these areas. This is important because leukaemia cells can hide in the brain and spinal cord, where many chemotherapy drugs cannot reach them effectively.^[11]

For some patients, particularly those with high-risk features or who don’t respond well to chemotherapy, doctors may recommend an allogeneic hematopoietic cell transplantation, also called a stem cell transplant or bone marrow transplant. This intensive procedure involves first using very high doses of chemotherapy (sometimes combined with radiation) to destroy all the patient’s bone marrow, including any cancer cells. Then, healthy stem cells from a donor are infused into the patient’s bloodstream. These donor cells travel to the bone marrow and begin producing new, healthy blood cells. The donor may be a family member with matching tissue type, an unrelated volunteer donor, or sometimes a partially matched family member in what is called a haploidentical transplant.^[17]

Stem cell transplantation carries significant risks, including infections while the immune system is rebuilding, and a condition called graft-versus-host disease where the donor cells attack the patient’s body. However, for high-risk patients, the procedure can offer the best chance of long-term cure because the donor immune cells can also attack any remaining leukaemia cells.^[15]

Chemotherapy and other treatments for leukaemia can cause various side effects because these drugs affect healthy cells as well as cancer cells. Common side effects include nausea and vomiting, hair loss, mouth sores, increased risk of infections due to low white blood cell counts, bleeding or bruising from low platelet counts, and fatigue from low red blood cell counts (anemia). Corticosteroids can cause mood changes, increased appetite, weight gain, and elevated blood sugar. Most side effects are temporary and improve after treatment ends, though some effects may be long-lasting. Doctors work closely with patients to manage side effects with supportive medications and other interventions.^[16]

Innovative Therapies in Clinical Trials

Beyond standard chemotherapy and stem cell transplantation, researchers are actively testing new and promising treatments for B-cell acute lymphoblastic leukaemia in clinical trials. Some of these innovative approaches have already shown remarkable results and may soon become part of routine care, while others are still in early stages of testing.

One of the most exciting developments is immunotherapy—treatments that harness the patient’s own immune system to fight cancer. A particularly promising immunotherapy drug is blinatumomab, which is a type of treatment called a bispecific T-cell engager or BiTE. This medication works by connecting T cells (a type of white blood cell that kills abnormal cells) directly to leukaemia cells, bringing them into close contact so the T cells can destroy the cancer. Blinatumomab specifically targets a protein called CD19 that is found on the surface of B-cell leukaemia cells.^[17]

Clinical trials have shown that blinatumomab can be highly effective for patients with Ph-negative B-cell acute lymphoblastic leukaemia who have detectable measurable residual disease after standard chemotherapy. When given to these patients, blinatumomab can eliminate the remaining cancer cells in many cases, potentially reducing the need for stem cell transplantation. The drug is given as a continuous intravenous infusion over several weeks, and researchers are now exploring whether adding blinatumomab to first-line treatment from the beginning might improve outcomes for all patients. Early results from these studies are very promising, showing high rates of remission with potentially fewer toxic effects than intensive chemotherapy alone.^[17]

Another immunotherapy being tested in clinical trials is inotuzumab ozogamicin, which combines an antibody that targets CD22 (another protein on B-cell leukaemia cells) with a toxic drug that kills cancer cells. When the antibody attaches to leukaemia cells, the toxic drug is delivered directly into those cells, sparing healthy tissue. Studies have shown that inotuzumab ozogamicin can be effective for patients whose disease has not responded to other treatments. Researchers are investigating whether combining this drug with chemotherapy from the start of treatment might improve outcomes while potentially reducing the intensity of chemotherapy needed.^[17]

For patients with Ph-positive leukaemia, newer-generation tyrosine kinase inhibitors are being tested in clinical trials. While imatinib was the first TKI used for this disease, newer drugs like dasatinib and ponatinib may be more powerful and can overcome resistance that sometimes develops to imatinib. Phase II clinical trials have tested these newer TKIs combined with reduced-intensity chemotherapy or even in sequence with blinatumomab, with some studies showing such impressive results that patients might eventually be able to avoid traditional chemotherapy altogether. These trials are exploring whether combining targeted drugs with immunotherapy could offer effective treatment with fewer side effects than conventional chemotherapy.^[17]

One of the most revolutionary approaches being studied is CAR T-cell therapy. This highly personalized treatment involves collecting a patient’s own T cells, genetically modifying them in a laboratory to recognize and attack leukaemia cells, and then infusing the modified cells back into the patient. The modified T cells are programmed to target CD19 on leukaemia cells. A CAR T-cell therapy called tisagenlecleucel (marketed as KYMRIAH) has been approved for children and young adults up to age 25 with B-cell acute lymphoblastic leukaemia that has relapsed (come back after treatment) or is refractory (hasn’t responded to treatment). About 20% of children with this cancer experience relapse or refractory disease, and CAR T-cell therapy offers a potentially life-saving option for these patients.^[9]

The process of CAR T-cell therapy takes several weeks from start to finish. First, doctors collect T cells from the patient’s blood through a procedure similar to blood donation. The cells are sent to a specialized laboratory where they are genetically engineered to express a chimeric antigen receptor (CAR) that recognizes CD19. After the cells are modified and multiplied, they are frozen and shipped back to the treatment center. Before the CAR T-cells are infused, patients typically receive a few days of chemotherapy to prepare their body. Then the modified cells are given through an intravenous infusion, similar to a blood transfusion.^[9]

Clinical trials for B-cell acute lymphoblastic leukaemia are conducted in phases that help researchers understand whether new treatments are safe and effective. Phase I trials primarily test the safety of a new treatment and determine the appropriate dose. These studies involve small numbers of patients and are the first time a new drug is tested in humans. Phase II trials enroll more patients and focus on whether the treatment works against the cancer—does it cause tumors to shrink or disease to go into remission? Phase II trials also continue to monitor for side effects. Phase III trials compare the new treatment directly against the current standard treatment to determine which approach works better. These large studies may involve hundreds or even thousands of patients at multiple medical centers.^[11]

Clinical trials for this disease are being conducted at major cancer centers throughout the United States, Europe, and other regions around the world. Eligibility for trials depends on many factors including the patient’s age, the specific characteristics of their leukaemia, what treatments they have already received, and their overall health status. Patients interested in clinical trials should discuss this option with their healthcare team, who can help determine whether any appropriate studies are available and assist with the enrollment process. Participation in clinical trials is always voluntary, and patients can withdraw at any time if they choose.^[11]

Most Common Treatment Methods

• Intensive Chemotherapy
  • Induction therapy using multiple drugs including vincristine, daunorubicin or doxorubicin, L-asparaginase, and corticosteroids to achieve remission
  • Consolidation therapy with high-dose chemotherapy to eliminate remaining cancer cells
  • Maintenance therapy with lower-dose oral and intravenous drugs continued for two to three years
  • Central nervous system prophylaxis to prevent leukaemia from spreading to the brain and spinal cord
• Targeted Therapy
  • Tyrosine kinase inhibitors (imatinib, dasatinib, ponatinib) for Philadelphia chromosome-positive leukaemia
  • These oral medications specifically block abnormal proteins that drive cancer cell growth
  • Allow reduction in chemotherapy intensity for many patients with Ph-positive disease
• Immunotherapy
  • Blinatumomab (bispecific T-cell engager) that connects T cells to leukaemia cells expressing CD19
  • Inotuzumab ozogamicin (antibody-drug conjugate) targeting CD22 on leukaemia cells
  • Particularly effective for patients with measurable residual disease or relapsed/refractory leukaemia
• CAR T-Cell Therapy
  • Tisagenlecleucel (KYMRIAH) for children and young adults up to age 25 with relapsed or refractory disease
  • Involves collecting patient’s T cells, genetically modifying them to attack CD19-positive cancer cells, and reinfusing them
  • Offers potential cure for patients whose cancer has not responded to standard treatments
• Stem Cell Transplantation
  • Allogeneic hematopoietic cell transplantation from matched sibling, unrelated, or haploidentical donors
  • Recommended for high-risk patients or those with inadequate response to chemotherapy
  • Combines high-dose therapy to eliminate bone marrow with infusion of healthy donor stem cells